Comparative Pharmacology
Head-to-head clinical analysis: DICLOXACILLIN SODIUM versus PENBRITIN S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICLOXACILLIN SODIUM versus PENBRITIN S.
DICLOXACILLIN SODIUM vs PENBRITIN-S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicloxacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and leading to cell lysis. It is resistant to penicillinase-producing organisms.
Penicillinase-sensitive penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
125-500 mg orally every 6 hours
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly/intravenously every 4-6 hours for moderate to severe infections.
None Documented
None Documented
Terminal elimination half-life: 0.6-0.8 hours in adults with normal renal function; prolonged to 1-2 hours in neonates, elderly, or severe renal impairment.
0.5-1 hour; prolonged in renal impairment (up to 7-10 hours in anuria).
Primarily renal: ~60-85% unchanged via glomerular filtration and tubular secretion; ~10% hepatobiliary (bile) and fecal; minor metabolism to penicilloic acid.
Renal: 75-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: ~10%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic